Electrocardiogram abnormalities with Atazanavir and Lopinavir/Ritonavir

HIV Clinical Trials

Volumn 10, Issue 5, 2009, Pages 328-336

  Rathbun, R Chris ^a   Liedtke, Michelle D ^a   Blevins, Steve M ^b   Harrison, Donald ^a   Lockhart, Staci M ^a   Salvaggio, Michelle ^b   Acosta, Edward P ^c  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse events; HIV; Pharmacokinetics; Protease inhibitor

Indexed keywords

ATAZANAVIR; LOPINAVIR; RITONAVIR;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; ATRIOVENTRICULAR BLOCK; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG SAFETY; ECG ABNORMALITY; ELECTROCARDIOGRAPHY; FEMALE; HEART BUNDLE BRANCH BLOCK; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PATIENT MONITORING; PR INTERVAL; PRIORITY JOURNAL; QRS COMPLEX; ULTRAVIOLET SPECTROSCOPY;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ARRHYTHMIAS, CARDIAC; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PYRIDINES; PYRIMIDINONES; RITONAVIR; TIME FACTORS;

EID: 70450200075     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1005-328     Document Type: Article

References (26)

1. Struble K, Murray J, Cheng B, et al. Antiretroviral therapies for treatment-experienced patients: current status and research challenges. AIDS. 2005;19:747-756.
2. Panel on Clinical Practices for the Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. June 17, 1998. Available at: http:// aidsinfo.nih.gov. Accessed September 5, 2008.
3. Boffito M, Maitland D, Samarasinghe Y, Pozniak A. The pharmacokinetics of HIV protease inhibitor combinations. Curr Opin Infect Dis. 2005;18:1-7.
4. Basso S, Solas C, Quinson AM, et al. Pharmacokinetic interaction between lopinavir/r and amprenavir in salvage therapy. J Acquir Immune Defic Syndr. 2002;31:115-117.
5. Kashuba AD, Tierney C, Downey GF, et al. Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results. AIDS. 2005;19:145-152.
6. Khanlou H, Graham E, Farthing C. Drug interactions between amprenavir and lopinavir/ritonavir in salvage therapy. AIDS. 2002;16:797-798.
7. Walmsley S, Leith J, Katlama C, et al. Pharmacokinetics and safety of tipranavir/ritonavir (TPV/r) alone or in combination with saquinavir (SQV), amprenavir (APV), or lopinavir (LPV): Interim analysis of BI1182.51. In: Program and abstracts from the XV IAS Conference; July 11-16, 2004; Bangkok, Thailand. Abstract WeOrB1236.
8. Rosenbach KA, Allison R, Nadler JP. Daily dosing of highly active antiretroviral therapy. Clin Infect Dis. 2002;34:686-692.
9. Cahn PE, Gatell JM, Squires K, et al. Atazanavir - a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials. J Int Assoc Physicians AIDS Care. 2004;3:92-98.
10. Haas DW, Zala C, Schrader S, et al. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial. AIDS. 2003;17:1339-1349.
11. Zilly M, Winzer R, Nolte C, et al. Double PI boosting with atazanavir and fos-amprenavir: favourable pharmacokinetics. In: Program and abstracts of the 6th International Workshop on Clinical Pharmacology of HIV Therapy; April 28-30, 2005; Quebec City, Quebec, Canada. Abstract 93.
12. Colombo S, Buclin T, Franc C, et al. Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures. Antivir Ther. 2006;11:53-62.
13. Vezina HE, Tschampa JM, Jennings C, et al. Steady-state pharmacokinetics (PK) of lopinavir/ritonavir (LPV/r) coadministered with atazanavir in HIV infected subjects. In: Program and abstracts of the 7th International Workshop on Clinical Pharmacology of HIV Therapy; April 20-22, 2006; Lisbon, Portugal. Abstract 48.
14. Ribera E, Azuaje C, Lopez RM, et al. Atazanavir and lopinavir/ ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen. AIDS. 2006;20:1131-1139.
15. Pham PA, Flexner CW, Parsons T, et al. Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ ritonavir. J Acquir Immune Defic Syndr. 2007;45:201-205.
16. National Cholesterol Education Program Risk Assessment Tool. Available at: http://hp2010.nhlbihin.net/atpiii/calculator.aspusertypeprof#moreinfo. Accessed July 10, 2009.
17. Product Information. Reyataz (atazanavir sulfate) capsules. Princeton, NJ : Bristol-Myers Squibb ; March 2008.
18. Eron JJ, Feinberg J, Kessler HA, et al. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naïve HIVpositive patients: a 48-week randomized clinical trial. J Infect Dis. 2004;189:265-272.
19. Busti AJ, Tsikouris JP, Peeters MJ, et al. A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV-positive patients. HIV Med. 2006;7:317-322.
20. Gianoti N, Guffanti M, Galli L, et al. Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir. AIDS. 2007;21:1648-1651.
21. Mahnke L, Child M, Satin L, et al. Electrocardiogram changes in HIV-infected, drug experienced patients treated with atazanavir. AIDS. 2008;22:1698.
22. Food and Drug Administration. Labeling changes for Kaletra refl ecting new QT/QTC interval and PR interval prolongation information 4/6/2009. Available at: http://www. fda.gov/oashi/aids/listserve/listserve2009.html#4709. Accessed May 8, 2009.
23. Hentig N, Kaykhin P, Stephan C, et al. Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimen. Antimicrob Agents Chemother. 2008;52:2273-2275.
24. Food and Drug Administration. Updated labeling for Norvir (ritonavir) soft capsule and oral solution. Available at: http://www.accessdata.fda.gov/ scripts/cder/drugsatfda/ index.cfmfuseactionSearch.Label-ApprovalHistory. Accessed September 5, 2008.
25. Rossi DR, Rathbun RC, Slater LN. Symptomatic orthostasis with extended-release nifedipine and HIV protease inhibitors. Pharmacotherapy. 2002;22:1312-1316.
26. Anson BD, Weaver JGR, Ackerman MJ, et al. Blockade of HERG channels by HIV protease inhibitors. Lancet. 2005;365:682-686.